The last decade witnessed the emergence of genomics, a set of high-throughput molecular measurements in biological samples. These pan-genomic and agnostic approaches have revolutionized the molecular biology and genetics of malignant and benign tumors. These techniques have been applied successfully to adrenocortical tumors. Exome sequencing identified new major drivers in all tumor types, including KCNJ5, ATP1A1, ATP2B3 and CACNA1D mutations in aldosterone-producing adenomas (APA), PRKACA mutations in cortisol-producing adenomas (CPA), ARMC5 mutations in primary bilateral macronodular adrenocortical hyperplasia (PBMAH) and ZNRF3 mutations in adrenocortical carcinomas (ACC). Moreover, the various genomic approaches -including exome sequencing, transcriptome, miRNome, genome and methylome -converge into a single molecular classification of adrenocortical tumors. Especially for ACC, two main molecular groups have emerged, showing major differences in outcomes. These ACC groups differ by their gene expression profiles, but also by recurrent mutations and specific DNA hypermethylation patterns in the subgroup of poor outcome. The clinical impact of these findings is just starting. The main altered signaling pathways now become therapeutic targets. The molecular groups of diseases individualize robust subtypes within diseases such as APA, CPA, PBMAH and ACC. A revised nosology of adrenocortical tumors should impact the clinical research. Obvious consequences also include genetic counseling for the new genetic diseases such as ARMC5 mutations in PBMAH, and a better prognostication of ACC based on targeted measurements of a few discriminant molecular alterations. Identifying the main molecular groups of adrenocortical tumors by extensively gathering the molecular variations is a significant step forward towards precision medicine.
Introduction
Adrenocortical tumors gather a large panel of diseases, mainly differing by their pathology -e.g. benign or malignant, focal tumor or diffuse hyperplasia -and by their secretion types and levels. Adrenocortical adenomas (ACA) are common and differ mainly by their secretion profiles. Indeed, the aldosterone-producing adenomas (APA) are responsible for primary aldosteronism, the cortisol-producing adenomas (CPA) are responsible for Cushing syndrome, while a majority of ACAs are nonsecreting adenomas. In-between are the subclinical Cushing adenomas responsible for subtle hormonal alterations but no overt clinical Cushing syndrome (1) . The adrenocortical hyperplasia includes several pathological forms. The primary bilateral macronodular adrenocortical hyperplasia (PBMAH) is probably the most common, potentially responsible for Cushing syndrome. The primary pigmented nodular adrenal dysplasia (PPNAD) is much rarer, but quite well individualized in terms of pathology, and responsible for overt Cushing. Other forms exist, with more intermediate features (2) . Finally adrenocortical carcinomas (ACC) are rare but overall aggressive tumors. However, the behavior of ACC differs between patients (3). Indeed a few carcinomas are of limited aggressiveness and can be cured by surgery, while others will not be cured by surgery, despite complete resection, even when localized to the adrenal gland.
A general hypothesis is that the variable presentations of adrenocortical tumors are related to tumor variability, at the molecular level. To test this hypothesis, new generations of tools have been recently used, able to catch extensively molecular variability. These tools, also called 'genomics,' were mostly developed during the last decade. Genomics is a set of ever improving highthroughput measurement techniques, measuring variability at different levels: at the gene expression level (transcriptome), at the miRNA expression level (miRNome), at the DNA methylation level (methylome), at the chromosomal structure level (copy-number alterations, loss of heterozygosity caught by SNP and CGH arrays) and at the DNA sequence level (mutations). All these genomic approaches have been recently applied to adrenocortical tumors, providing an agnostic molecular classification, leading to better classification and better understanding of pathophysiology.
The aim of this review is to show how genomics changed our knowledge of adrenocortical tumors and to present the clinical perspectives of this new knowledge.
Methods
The published literature on the genomics of adrenocortical tumor was screened using the following search terms on PubMed between 2009 and October 2015: '(adrenal OR adrenocortical) AND (hyperplasia OR adenoma OR dysplasia OR cancer OR carcinoma).' Review articles were also considered, and their reference lists were screened for additional relevant publications.
Exome sequencing of adrenocortical tumors: it's raining genes! Before the genomic era, after two decades of candidate gene approaches, half a dozen of driver genes were identified for different adrenocortical tumor types. These drivers include mainly TP53 inactivating mutations in ACC, CTNNB1 activating mutations in ACA and ACC and mutations activating the cAMP/protein kinase A (PKA) pathway in ACA and adrenocortical dysplasia/hyperplasia -including PRKAR1A inactivating mutations, PDE8B and PDE11A inactivating mutations, GNAS activating mutations (4) - (Table 1, Fig. 1B ). Since the recent rise of next generation sequencing and in particular exome sequencing, it took only 4 years to identify a new dozen of driver genes in these tumors (Table 1) . subsequent Gq/phospholipase C signaling -and the plasma membrane depolarization -with subsequent opening of calcium voltage-dependent channels -respectively (6) . In APA, the new mutated genes also demonstrate the central role of intra-cellular calcium for autonomous aldosterone production. This intra-cellular calcium raise is either related to mutations in ion transporter genes (KCNJ5, ATP2B3 and ATP1A1) inducing a plasma membrane depolarization with subsequent opening of voltagedependent calcium channels (5, 7, 8) , or to mutations in voltage-dependent calcium channels (CACNA1D and CACNA1H) inducing the opening at lower thresholds of membrane depolarization (8, 9) (Fig. 1D ).
The majority of these mutations were identified in the somatic compartment, by comparing the APA (tumor tissue DNA) exome to the germline (leucocyte DNA) exome. In the germline compartment, rare instances of mutations were also identified for KCNJ5, CACNA1D and CACNA1H, mainly in families with primary aldosteronism, and as de novo mutations (5, 9, 10) .
The molecular alterations in the zona glomerulosa may be more complex. Indeed recently Fernandes-Rosa et al. (11) identified different somatic mutations in the adrenals of patients presenting an APA with multiple nodules. In addition, Nishimoto et al. (12) reported somatic mutations in CACNA1D, ATP1A1 and ATP2B3 in 'normal adrenals' -e.g. from patients not included as presenting a primary aldosteronism. These mutations were identified in clusters of glomerulosa cells with elevated expression of CYP11B2, and different mutations could be found in different such clusters within the same adrenal (12).
Beyond the calcium signaling, the Wnt/b-catenin seems to be another major player in APA (Fig. 1) . Berthon et al. (13) recently reported Wnt/b-catenin activation in a majority of APA, related to the downregulation of a negative regulator of this pathway, named SFRP2 -this Familial adenomatous polyposis downregulation seems to be due to a high methylation of SFRP2 promoter (13) . Another recent publication identified CTNNB1 mutations -encoding the b-catenin -in Conn adenomas in pregnant women (14) . The relationship between the calcium signaling activation and the Wnt/b-catenin pathway remains to be elucidated.
CPA: mutations of the PRKACA
In 2014, four independent research teams identified activating mutations of PRKACA -the alpha subunit of PKA -in CPA (15, 16, 17, 18) . As for APA, CPA exome was compared with the germline exome, leading to the 
G1 S

Apoptosis
DNA damage
CDK4
Cell-cycle
European Journal of Endocrinology
Review S Faillot and G Assie Genomics of adrenocortical tumors
www.eje-online.org identification of a hotspot mutation transforming a Lysine into an Arginine at position 205 (L205R). These studies and subsequent ones identified this mutation in 22-50% of CPA associated with overt Cushing (15, 16, 17, 18) . In physiology, activation of the cAMP/PKA pathway is central in zona fasciculata cells for the cortisol production. This pathway is activated by the binding of ACTH to its receptor MC2R, subsequently activating Gs, then adenylyl cyclase and finally PKA. In CPA with the L205R mutation, the autonomous cortisol production results from direct activation of PKA (19) . Indeed, the PRKACA L205R mutation was shown to increase PKA activity (15, 17) . These PRKACA mutations add to previously reported GNAS (20) and PRKAR1A (21) mutations, identified in rare instances of CPA and also activating the cAMP/PKA pathway ( Fig. 1) .
In addition to these mutations activating the cAMP/PKA pathway, mutations of CTNNB1 -activating the Wnt/b-catenin pathway -have also been reported in adrenocortical adenomas, found in about 25% of cases (22) . Adenomas with CTNNB1 mutations are bigger and secrete less cortisol than their WT counterparts (23) . Of note, the CPA with PRKACA mutations reported recently do not often harbor CTNNB1 mutation (15, 16, 17, 18) . Are these mutations somehow mutually exclusive? Is there any interplay between the Wnt/b-catenin and the AMPc/PKA pathway? These points remain to be clarified.
ARMC5, a new gene predisposing to PBMAH
Though being bilateral and a global adrenal cortex disease, adrenal hyperplasia has not clearly been deemed as genetic diseases until recently, at least in its most common macronodular subtype. Indeed only rare families have been reported, and mutations in several genes (PRKAR1A, PDE11A, PDE8B, GNAS, PRKACB, MEN1 or FH among others; review in (4, 24, 25) ) have been identified only in rare instances and or specific subtypes of these diseasessuch as PRKAR1A mutations in PPNAD.
In 2013, we identified ARMC5 mutations in 50% of PBMAH patients requiring an operation (26) . This gene was identified by comparing the macronodules to germline DNA. A SNP array approach first identified a somatic copy-neutral loss of heterozygosity in chromosome 16p in 25% of patients. An additional whole-genome sequencing identified mutations of ARMC5, located in 16p. ARMC5 is a typical tumor suppressor gene, with two hits identified in each macronodule: a first germline hit -found in all the tissues and all the adrenal macronodules of each patient -and a second somatic hit -specific of each adrenal macronodule (26) .
Subsequent studies identified a prevalence of 25-50% of ARMC5 mutations in PBMAH (27, 28, 29) . Patients with ARMC5 mutations seem to present a more severe Cushing syndrome and a more nodular adrenal shape than their WT counterparts (29) . Alencar et al. (27) also reported a large family with ARMC5 mutations, giving important insight on the penetrance of the disease.
ARMC5 is a 'new gene,' poorly characterized in terms of function. ARMC5 inactivating mutations were shown to decrease steroidogenesis and to reduce apoptosis in adrenocortical cells (24) . Its precise role remains to be established. Does ARMC5 play a role in the recently reported intra-adrenal ACTH production (30) or with the aberrant GPCR expression profiles (31)? Further studies are needed.
The mutation landscape of ACC: a reduced number of genes with recurrent mutations
In 2014, we reported the first ACC genomic landscape based on exome sequencing and SNP arrays -the latter technique is convenient for detecting homozygous deletions and high-level amplifications -comparing the tumor to germline DNA (32) . The cancer genome atlas (TCGA) consortium has also recently presented the mutational landscape on a large cohort of ACC, also comparing the tumor and the germline exome (33). Juhlin et al. (34) also reported a few months ago another analysis of the ACC exome, using a similar strategy. These studies converge on a reduced list of recurrent ACC drivers (Table 1) . Two other studies used next generation sequencing to characterize the mutations in ACC, analyzing the genetic variation of a limited number of cancer-related genes, and restricting the analysis to the tumor DNA (35, 36) .
Among these drivers, ZNRF3 appeared as the most commonly altered gene in ACC, found in more than 20% of ACCs (32, 33, 34) . This is also the first report of ZNRF3 alterations in cancer. ZNRF3 is an E3 ubiquitin ligase, with a negative regulator function of the Wnt/b-catenin pathway (37) . In ACC, ZNRF3 is inactivated, mainly by homozygous deletions, but also by mutations (32, 33, 34) . This suggested that ZNRF3 inactivation induces an activation of the Wnt/b-catenin pathway (Fig. 1) . The Wnt/b-catenin pathway can also be activated directly in ACC by CTNNB1 activating mutations (22) -encoding the b-catenin -also commonly found in ACCw15% of ACC (32, 33, 34) . Interestingly and logically,
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www.eje-online.org ZNRF3 and CTNNB1 mutations are mutually exclusive in ACC (32, 33, 34) . Other recurrently mutated genes are related to the cell-cycle regulation. Among these, TP53 mutations are found in w15% (32, 33, 34) . Other genes regulating the cell-cycle and commonly altered in cancer are altered in ACC, including the tumor suppressors CDKN2A and RB1, and the oncogenes MDM2 and CDK4 (32, 33, 34, 36, 38, 39) (Table 1) . These alterations globally unbrake the cell cycle, one of the key elements of cancer proliferation (Fig. 1A) .
Other pathways emerging from the genetic landscape of ACC include the chromatin remodeling -with mutations of MEN1, DAXX and ATRX -and the chromosome maintenance -with TERT and TERF2 amplifications (32, 33, 34, 36) .
A few other recurrently mutated genes have been identified, including PRKAR1A and RPL22 (33). PRKAR1A mutations had been previously identified in PPNADs and in some CPA (see previous paragraph). These instances of ACC with PRKAR1A mutations raise the question of the potential role of the cAMP/PKA pathway in some ACC, and subsequently of the potential predisposition to ACC in the benign adrenal tumors with activated cAMP/PKA. Further studies are needed to clarify this point.
Finally other genes are altered, with no clear recurrence among ACC ('private' mutations). The global importance of these genes in ACC pathophysiology remains to be clarified.
Of note, none of these alterations oriented obviously towards the use of any targeted cancer therapy commonly available and used in other cancers.
Integrated genomics of ACC identify distinct molecular groups with different outcomes
Several teams focused on the genomics of ACC (Table 2) , showing major differences between ACC and ACA, and identifying molecular subgroups of ACC, with different outcomes.
Common molecular features of ACC
ACCs share common molecular characteristics (Table 2) . At the transcriptome level, thousands of genes are deregulated, in comparison to ACA. A large proportion of these genes is implicated in the cell-cycle regulation, chromosomal maintenance, survival, inflammation, immunity and the global modulation of gene expression, as part of a global 'malignancy signature' (40) . This type of gene expression signature is shared by many different cancer types, independently of the tissue of origin. In addition to these unspecific malignancy features, the ACC specifically show a global decrease in expression of genes related to steroidogenesis, reflecting the dedifferentiation of ACC cells (41, 42, 43, 44, 45, 46, 47, 48, 49) . Finally massive IGF2 over-expression is one of the most striking differences between ACC and ACA, observed in O85% of ACC (41) . This was known before genomics, first observed in congenital Beckwith-Wiedemann syndrome (50) . IGF2 over-expression is considered as an early tumorigenesis event, activating the IGF1 receptor (51) .
miRNAs are small untranslated transcripts, regulating the gene expression level by RNA-interference. Several hundreds of miRNA have been identified in humans. The miRNome of ACC shows globally several miRNA differentially expressed compared with ACA. The most consistent one is the overexpression of miR-483-5p (52, 53, 54) , in which gene is located in IGF2 gene locus, and probably deregulated simultaneously with IGF2. Other deregulated miRNAs include downregulation of miR335 and miR195 (47, 52, 53, 54, 55, 56) among others. There is currently no precise determination of the global impact of these miRNA deregulations on gene expression in ACC.
In terms of DNA methylation, ACC are globally hypomethylated compared with ACA (57). This hypomethylation is mainly related to hypomethylation in intergenic regions of DNA, probably contributing to the genome instability, as seen in cancer in general (58) . Beyond this global hypomethylation, a subset of ACC shows specific patterns of methylation, with hypermethylation in CpG islands of gene promoter regions (59) . This point will be detailed in the next paragraph.
Finally the ACC genome tends to be altered compared with ACA, with extended chromosomal gains, losses and losses of heterozygosity in a majority of ACC (60, 61, 62, 63) .
Genomics identify different molecular groups of ACC
The major finding of the integrated genomics of ACC is the existence of distinct molecular subgroups. Remarkably, these distinct groups are strongly associated with the patient's outcome.
At the transcriptome level, two main distinct subgroups have been defined, strongly associated with prognosis (33, 42, 64) . At the miR level, 2-3 subgroups are reported, also associated with different outcomes (32, 33, 54, 55) .
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At the DNA methylation level, an important variability occurs when focusing on the methylation of gene promoter regions, in regions enriched in 'CG' bases (called CpG islands) (57, 59) . Indeed some ACC are hypermethylated in these regions, evoking a CpG island methylator phenotype (CIMP), as described in other malignancies such as colon cancer (65) . In ACC, CIMP is associated with a poor outcome (59) .
As stated in the previous paragraph, recurrent somatic mutations have been found in w50% of ACC (32, 33, 34) . These ACC are associated with a poorer outcome.
These omics classifications have been extensively generated in two independent international cohorts of ACC: one from Europe (European Network for the Study of Adrenal Tumors) (32, 33) and one from the TCGA ACC Group from America, Europe and Australia (32, 33) . A global molecular classification has emerged from these studies, highly consensual (32, 33) . Indeed, a strong agreement was found between the different omics classifications, defining two main molecular groups. Interestingly these two groups are associated with a quite different outcome. Finally a more granular classification can isolate a third molecular subgroup, associated with intermediate survival (Fig. 2) . The TCGA cohort should be published soon, warranting a more detailed comparison with the ENSAT cohort.
The molecular group of ACC with better outcome
In terms of transcriptome, the molecular group of ACC with better outcome shows a higher expression of genes intervening in cell metabolism, intracellular transport, cell differentiation and in apoptosis (42) . These tumors have a low mutation rate, and scarcely harbor mutations in the recurrently mutated genes described in the previous paragraph (32, 33) . Instead private mutations can be observed. Finally in terms of DNA methylation, these tumors do not show any CIMP (32, 33) (Fig. 2) . 
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Though being of better outcome, with few recurrences after surgery, these tumors do correspond to malignant tumors in terms of molecular profiling, and not to benign tumors. Indeed the transcriptome and miRNome profiles of these tumors are much closer to the transcriptome of other ACCs, the aggressive ones, compared with ACAs. In addition the chromosomes of these tumors are extensively altered in a majority of tumors, a feature not observed in ACAs (60, 62, 63) . Finally, in our study, a majority of these tumors have an elevated number of malignancy features as defined by pathology, scored by the Weiss score, whereas almost all the tumors defined as benign by the transcriptome show evident pathological features of ACA with Weiss scores of 0 or 1 (42) . Interestingly in this study seven tumors show borderline pathology, corresponding to Weiss scores of 2 or 3. Six out of seven are classified as malignant by the transcriptome, including four in the molecular group of better outcome (42) . This suggests that adrenal tumors with borderline pathology are probably malignant in terms of molecular profile. Larger cohorts are needed to confirm this finding.
The molecular group of aggressive ACC
In terms of transcriptome, the molecular group of aggressive ACC shows a higher expression of cell-cycle related genes (42, 64) . In terms of mutations, these tumors accumulate alterations on the recurrent ACC drivers reported in the previous paragraph (32, 33, 34) (Table 1) .
In terms of pathology, Giordano et al. (64) suggested that this group of ACC is of 'higher grade,' as defined by increased proliferation index -e.g. high Ki67 immunopositivity and high mitotic count. The transcriptome signature is indeed in agreement with the notion of increased proliferation. However, despite a significant difference in terms of proliferation index between the two main molecular types of ACC, this criterion is not sufficient on its own to discriminate. Indeed in this study, some low grade ACC are observed in the transcriptome group of poor outcome, and some high-grade ACC are observed in the transcriptome group of better outcome (64) . This relationship between proliferation index and molecular classification deserves further studies on larger cohorts. If these discrepancies are confirmed, it will be of major interest to specifically determine the prognosis of ACC with discrepant proliferation index and molecular group. Finally Ki67 reproducibility and mitotic count are not absolute (66) . Of note, the reproducibility of the discriminant molecular measures within a single ACC has not been tested yet.
Within the group of aggressive ACC, a subset of tumors shows hypermethylation on CpG islands in genes promoters (CIMP). This hypermethylation is associated with a poorer prognosis compared with tumors with no hypermethylation (32, 33) . Therefore methylation probably further divides the group of aggressive ACC into one subgroup of poorer outcome, and another subgroup of intermediate outcome. Further studies are needed to confirm this observation.
None of the driver genes is known to impact directly DNA methylation, and the specific methylation pattern associated with a poor outcome -e.g. CIMP -is not explained yet in terms of underlying mechanisms. The link between driver mutations and transcriptome can probably be partially explained: mutations in drivers such as TP53 or CDKN2A probably contribute to the cell-cycle signature identified in the subgroup of poor outcome, as observed in other cancer types, though the precise transcriptome signature induced by each driver mutation in adrenal cells is not precisely established. Finally, concerning the link between methylation and transcriptome, the CIMP is potentially responsible for modulating the expression level of 15% of genes (59) .
Clinical implications of the genomic knowledge
The genomics findings have clinical implications for adrenocortical tumors.
Towards an improved nosology of adrenocortical tumors?
Before genomics, gold standards for classifying the tumors were based on a combination of pathology, hormonology and clinical outcome. Genomics provide agnostic molecular classifications. Can these molecular classifications help to better define the different diseases and their subtypes? Possibly.
For primary aldosteronism, can we properly discriminate a true APA, from an adrenal incidentaloma associated with a diffuse or multifocal zona glomerulosa disease? The adrenal vein sampling performed before surgery warrants somehow this problem by demonstrating the asymmetry of aldosterone secretion between the two adrenal glands. However the thresholds are often discussed and asymmetric forms of hyperplasia have been reported (67) . 'Functional pathology' has emerged as a potential way to confirm the diagnosis of APA. The strategy is to ascertain the expression of aldosterone synthase (CYP11B2) -the
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www.eje-online.org key aldosterone producing enzyme -in the adenoma. This was first achieved by in situhybridization and more recently by immunohistochemistry (see (6) for review). Genomics has brought up the knowledge of somatic mutations in APA (affecting KCNJ5, ATP2B3, ATP1A1 and CACNA1D), and finding such a mutation may also be a way to ascertain the true nature of an APA. The potential benefit of this genotyping in clinical practice remains to be established. For instance will it be possible to use molecular markers for preoperative diagnosis, such as detecting the somatic mutations in the patient's plasma from the cell-free tumor DNA, or detecting circulating miRNA signing the presence of an APA? Bilateral adrenal hyperplasia include a wide spectrum of pathological aspects -including mainly macronodular and micronodular hyperplasia, hyperplasia with no nodule, and PPNAD -and are associated with different levels of cortisol secretion (2) . Are these diseases different, or are they variations of a single disease? Genomics finding help to clarify this question, especially with the discovery of driver genes defining specific diseases. The most obvious example is the PRKAR1A mutation in PPNAD. In PPNAD there is globally a good agreement between the genotype and the pathological phenotype -micronodules, adrenal atrophy between the nodules and pigmented spots. However some PPNAD do show macronodules (68) (often harboring a somatic CTNNB1 mutation), and reversely, no PRKAR1A mutation is found in w30% of PPNAD. Are these PPNAD a different disease? With genomics another gene, ARMC5, was recently discovered. ARMC5 mutations seem to be related to a phenotype with several macronodules, and in the index cases more often an overt Cushing syndrome (29) . Meningiomas may also be associated with the disease (69) . However more than 50% of these hyperplasias are not related to ARMC5. Are these different diseases? How many diseases? Associated with which phenotype? With which secretion level? Identifying the molecular drivers of these diseases could help to better classify these diseases.
Genetic counseling for the new genetic diseases
Some adrenal tumors are hereditary genetic diseases. From the genomic studies, drivers have been identified, opening new possibilities for genetic counseling. In PBMAH patients with ARMC5 mutations, a genetic screening can be proposed to the relatives. The first estimation of the penetrance arises from the large Brazilian family reported by Alencar et al. (27) . This genetic screening is important because the long term consequences of hypercortisolism, progressively starting subclinical, should be prevented in ARMC5 mutations carriers, through early and aggressive correction of mild complications -hypertension, diabetes, osteoporosis -and early medical treatment or adrenalectomy if required.
In primary aldosteronism, familial forms with KNCJ5 mutations have been reported (6) . Here again, screening the relatives should help to identify the patients at risk, and diagnose and treat early their hypertension. However these familial forms seem very rare compared with the vast majority of sporadic diseases related to somatic mutations.
A better diagnosis and a better determination of prognosis for ACC patients Genomic studies clearly discriminate benign from malignant carcinomas. There is probably no need for sophisticated molecular tool when the pathological diagnosis is obvious, either for benign tumors with Weiss scores of 0 or 1, or for malignant tumors with Weiss scores of 4 or more. However in several situations, molecular diagnosis may be relevant. First, tumors with borderline pathologyespecially those with Weiss scores of 2 or 3 -may be properly classified with molecular tools. As stated previously, in our study a majority of these tumors are most often malignant in terms of molecular profile (42) . Confirmation is necessary on larger series. Another question is about the inter-and intra-observer variability of the pathological criteria from the Weiss scoring system (66) . Can molecular diagnosis help to limit the impact of this variability? To which extent is a molecular assessment reproducible? This remains to be determined. Finally diagnosing malignancy may not be trivial in specific subtypes such as the oncocytic variants of adrenocortical tumors. A specific scoring has been proposed by Biseglia et al. (70) . Would a molecular diagnostic tool be relevant for such tumors? This remains to be determined.
Another question is about the potential malignant evolution of an ACA. Does it exist? Is there an ACA to ACC sequence? Epidemiology does not plead in favor of this sequence, considering the contrast between the high prevalence of adrenal ACA and low prevalence of ACC. However, rare cases of ACC in patients with ACA or hyperplasia have been reported (discussed in (63) ). Genomics also brings some information. The most remarkable is the high proportion of CTNNB1 mutations in both ACA and ACC. In addition, CTNNB1-mutated ACA are bigger and secrete less cortisol (23) Concerning other omics, it is hard to draw any conclusion about any potential ACA to ACC sequence from transcriptome, miRNome and methylome. Finally a few chromosomal alterations common to ACA and ACC have been identified (63) , but no definitive conclusion can be drawn either. Among ACC, distinct molecular subgroups have emerged from genomics, associated with different outcomes. This information is of major importance, especially if it is possible to discriminate ACC potentially curable by a complete surgery from ACCs with later recurrences despite a complete (R0) surgery. There is here a unique opportunity to classify the ACC patients in distinct mechanistic and prognostic groups (Fig. 2) . We proposed a tool to discriminate the two transcriptome groups of ACC, and could recapitulate the whole transcriptome information with the expression of two genes, BUB1B and PINK1. This tool was further validated by Fragoso et al. (71) , and is currently prospectively tested in a routine clinical laboratory at our institution. As stated in the previous paragraphs, other omics help to classify the ACC, such as DNA methylation and recurrent drivers sequencing. This information could also be important for optimal oncogenetic classification. However it will be necessary to promote additional studies to confirm the predictive value of each of these molecular markers, precisely determine the interactions between these markers, and assess the benefits compared with the already existing prognostic markers -especially the proliferation index.
The success of molecular tools in clinical practice will also depend on the simplicity, the robustness and the price of the molecular tools. As stated before, gene expression, but also miRNAs can be conveniently assayed by quantitative RT-PCR. Concerning methylation, the CIMP can be recapitulated by focal measurements of methylation, using methylation-specific multiplex ligation probe assay, a technique widely available in oncogenetic departments (59) . Finally targeted sequencing of driver genes can be performed by next generation sequencing (35, 36) . In theory all these techniques are easily applicable.
Molecular findings from genomics should also open the way to liquid biopsies in a close future. These include a set of measurements in the blood reflecting the molecular features of the tumor. The most straightforward application is the detection of cell-free tumor DNA in patients' plasma by catching in plasma a specific tumor mutation, used as a proxy of tumor DNA (72) . We should be able to use CTNNB1 mutations, mutated in w15% of ACC, and corresponding usually to a limited number of mutation hotspots. Such hotspots should be detectable prior to surgery. After surgery, sequencing one patient's tumor should help to identify specific mutations that could be later used as proxies for monitoring the remaining tumor DNA, and therefore the remaining tumor tissue. Another application is the detection of circulating miRNAs signatures, also reflecting the diagnosis, and potentially the prognosis of an ACC (54) .
Towards new treatments of adrenocortical tumors?
In APA, many patients present a somatic mutation increasing the intracellular calcium by depolarizing the plasma membrane implying the opening of voltagedependent calcium channels. These patients may benefit from calcium channel blockers, beyond the antihypertensive effect of these treatments (see (6) for review).
For ACC patients the medical therapies currently available are of limited efficiency, and there is a crucial need for new treatments. Genomics may help to identify new therapeutic targets. However the exome sequencing of ACC did not identify directly drugable-molecular alterations, considering the drugs currently commonly available. Especially, no tyrosine kinase mutation could be recurrently found (32, 33, 34) . However the genomic analyses have identified and/or confirmed the implication of a few cardinal signaling pathways. These include mainly the Wnt/b-catenin signaling and p53/Rb signaling. These pathways are commonly deregulated in cancer, and important effort is now put to try and develop drugs specifically targeting these pathways in cancer, without altering too much these essential pathways in all other cells. For instance, several inhibitors of the Wnt/b-catenin pathway have been identified (73) . In contrast, successes in targeting p53/Rb pathway have been limited so far, despite wide efforts. Hopefully this field of research will benefit to ACC patients in a close future.
Genomics may also help ACC patients through new generations of treatment. One example is the RNA interference therapy, a promising strategy for targeting molecular alterations. The team of Sidhu proposed to target these tumors using miR-7 (74) . The genomic classification may also help to propose a new algorithm for treating ACC patients, based on a better risk stratification. Indeed, ACC showing the molecular features associated with a better outcome could probably be proposed a simple follow up as far as a complete surgery
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www.eje-online.org could be performed, and in case of recurrence the preferred use of repeated loco regional treatments over systemic treatments. On the opposite, ACC with molecular features associated with a poor outcome could be proposed systemic therapies in priority, even adjuvant systemic therapies after an apparently complete surgery. Such clinical recommendations based on the molecular classification, would need to be validated by prospective clinical trials.
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